...SANOFI: Example Class Lecture CBA University provides the students with an example class, in which they let them, see and experience how companies work. We were fortunate to see one of our graduate working for one of the most knowable multinational pharmaceutical company. It was motivating to see how successful she was since she graduated and I believe it was an honor to be back as a representative and to give an overall introduction to a well-known company in a class she used to take. In this example class she talked about her company SANOFI, what they do, the pharma industry dynamics, and business to business modem. At first we did not know what was SANOFI? She said it was for private reasons, because they don't promote it directly to consumers but actually though healthcare professionals. She continued talking about SANOFI which is the fourth leading pharmaceutical company with revenue of €33 billion from last year. SANOFI offer both chemical and biological molecules which is becoming 8% of SANOFI research and development. The company has a diversified offer therefor they don't just make drugs but also healthcare solutions, devices and vaccines. SANOFI is present in 100 countries including Saudi Arabia. It has over 110.00 employees all over the world and with a 112.00 industrial site. SANOFI has a long heritage it established in 1718 and it went through a lot of merges with other companies. It went from SANOFI to Sanofi-Synthélabo to Sanofi-Aventis in 2004 and finally...
Words: 907 - Pages: 4
...Introduction The world is a cold place these days for businesses seeking profitable international growth. In a few industries, firms have to be global if they are to achieve leadership. Implementing a global expansion strategy is crucial to the growth of a business from small start-up to international brand name. Companies such as McDonald's, Home Depot, Starbucks and more have made their presence known around the world over the past few decades. However, each global expansion presents its own set of obstacles which the parent company must tackle, in order to be successful in their global expansion. In a borderless world, companies need to compete on a global level in order to succeed. In today's world of financial uncertainty, it is important for businesses to have a clear idea of what stability involves for their company. One concept that more and more businesses are exploring is one of taking their business to a global level. Using an international strategy is not for every company, but with the availability of the Internet it is becoming easier to take your business to that next level. Global expansion may enable a firm to earn greater returns by transferring the product offerings derived from its core competencies to markets where indigenous competitors lack those product offerings and competencies. One of the global expansion strategies is merger and acquisition. Five waves of mergers and acquisitions took place in the 20th century, with the last two occurring...
Words: 4340 - Pages: 18
...Organizational Structure Paper Brianne Fluegel MGT/230 March 2nd, 2015 Sylvester Taylor Organizational Structure Paper There is no better way of knowing a certain organization than actually working for them. Sanofi Pasteur, my employer, is a global pharmaceutical company. Sanofi is broken off into a few different companies, Sanofi Aventis, Sanofi, and Sanofi Pasteur. Each division has its own distinct purpose. My employers purpose at Sanofi Pasteur is formulate, fill, inspect, and package vaccines. The motto of the company is that we may live in a world where no one suffers or dies from a vaccine preventable disease and that is what the company focuses on. There are constantly new trials and on going research for new vaccines, improving the ones we already have, and expanding our reach to the world. Some diseases that we prevent with our vaccines are Influenza, Tetanus, Meningitis, Yellow Fever, Pertussis, and Dengue Fever. In order for a company that is so large and influential to be successful, the organizational structure of the company must be strong and clear. Sanofi Pasteur operates within a vertical structure. The hierarchy is run from the board of directors, to the CEO and president, to top level managers, mid level managers, and lower level managers. The company just named a new CEO to start on April 1st, 2015 after removing the previous CEO. The board, CEO, and president operate the company from France, not on our actual production campus. On campus we have...
Words: 1075 - Pages: 5
...International Strategy Assignment ¼ What are the main benefits that your company enjoys due to itsinternational presence? What are the keychallenges your company faces due to its international exposure ? First major benefit Sanofi Aventis enjoys from international presence is Economies of Scale. International expansion means access to a larger market and implies higher potential sales as well as manufacturing volumes. Research and Development of new products incorporate the most important fix cost for pharmaceutical companies. The general industry trend suggests that although non-R&D costs have declined recently, the cost of bringing new product to a market rose in two-digit rate and this development will continue (http://www.guardian.co.uk/business/2011/nov/21/pharmaceuticals-drug-research-costs-rise). Therefore the efficiency gains resulting from higher production level are even more crucial. Another benefit Sanofi Aventis enjoys is improved responsiveness to customer needs. The demand for pharmaceutical products is increasing around the globe, especially in BRIC countries. Therefore it was essential to establish international network of sites and sales channels in order respond to demand in flexible and timely manner. Additionally in order to ensure the product effectiveness it is sometimes important to conduct trials with local population that share characteristics distinct from other regions. Next important benefit are the location advantages. The sites Eastern Europe...
Words: 662 - Pages: 3
...Assignment On Mission Statement Analysis of five Companies Mission statement: The mission of a company is its unique purpose which sets a firm apart from other firms of its types and identifies the scope of its operations in products and market terms. In general terms, mission statement addresses the following questions: • Why is the firm in business? • What are our economic goals? • What is our operating philosophy in terms of quality, company image and self concept? • What are our core competencies and competitive advantage? • What customers do and can we serve? • How do we view your responsibilities to stockholders, employees, communities, environment, social issues and competitors? Components of mission statement: • Specifies basic type of product or service to be offered • Identifies primary market or customer to be served • Specifies technology to be used in productionor delivery • Reflects the firms fundamental concern for survival through growth and profitability Newest trend in mission components: • Sensitivity to customer wants • Concern for quality • Statements of company mission [pic]Company Background: |Saint-Gobain Crystals & Detectors is a business unit of Saint-Gobain Ceramics & Plastics Inc., a subsidiary of Compagnie de | |Saint-Gobain headquartered in Paris, France. | |Saint-Gobain...
Words: 3086 - Pages: 13
...these drugs are. These drugs are controversial across the board considering the significant increase of usage primarily amongst high school aged students. Leaving the societal and physiological part of the argument aside, an inescapable truth is that there is an increase of usage for these products and that means someone somewhere is having an increase in profits. Perhaps pharmaceuticals aren't the next .com bubble, but taking a look at some of the biggest firms might be useful for a budding portfolio manager. This article will look at the three biggest pharma companies, and next weeks article will look at some of the most promising start up pharma companies. The three biggest companies in the world according to Forbes are: Pfizer, Novartis, Sanofi respectively. Pfizer is the largest pharmaceutical company in the world and has posted fairly steady gains over the last three years (Forbes, Bloomberg, Morningstar). According to Peter Lynch in his book “One Up On Wall Street,” this company would be an example of a stalwart (Peter Lynch 'One up on Wall Street'). That means that this company will not give you huge returns, but will provide consistent returns with relatively low volatility. Pfizer is perhaps the most well known of pharmaceutical stock options, but it might not necessarily be the best of options. Novartis has had similar amounts of revenue, but has had less goodwill and long-term debt (Morningstar). Knowing what to look for in a company is sometimes tricky, and I won't pretend...
Words: 576 - Pages: 3
...Pharmaceutical Sector of Bangladesh The pharmaceutical industry in Bangladesh is one of the most developed technology sectors within Bangladesh. Manufacturers produce insulin, hormones, and cancer drugs. This sector provides 97% of the total medicinal requirement of the local market. The industry also exports medicines to global markets, including Europe. Pharmaceutical companies are expanding their business with the aim to expand the export market. History Right after liberation war three fourth of the pharmaceutical industries was dominated by multinational companies. The National Drug Policy (NDP) in 1982 and 2005 has major impact in the development and growth of the Bangladesh pharmaceutical industry. Key points of National Drug Policy of 1982 To provide administrative and legislative support for ensuring quality of essential drugs which are relevant to the national health need. To reduce the price of medicine by ensuring the lowest competitive price. To eliminate non-essential medicine from the market To promote production of local drug and raw materials. To develop proper drug monitoring and information system to prevent wasteful misuse and to ensure the proper utilization of the drugs. To ensure GMP and qualified pharmacist in manufacturing companies. Drug Regulatory Authorities in Bangladesh • The Directorate General of Drug Administration (DGDA) • The Pharmacy Council of Bangladesh (PCB) Local Market Overview The Bangladesh...
Words: 998 - Pages: 4
...UNIFORM CODE OF PHARMACEUTICAL MARKETING PRACTICES The Indian Pharmaceutical Industry is one of the most rapidly growing science based industries in terms of remarkable capabilities in both the manufacture and technology. India being among one of the five pharmaceutical emerging markets has an average annual growth of 8-9 percent with an approximate worth of $ 4.5 billion. With more new drug launches, new drug applications, phase II clinical trials taking place this year the growth can be expected to be 13-14 percent in the future. Considering the rise in the pharmaceutical sector and to bring about uniformity in the marketing of these drugs, a Code has been introduced by the Department of Pharmaceuticals (DoP), Government of India. This code named as Uniform Code of Pharmaceutical Marketing Practices (UCPMP) was introduced on December 12, 2014 and became effective from January 01, 2015. UCPMP initially set to be a voluntary code for the Pharmaceutical Industries was then decided to be made as statutory Code when DoP was urged by the Organization of Pharmaceutical Producers of India (OPPI). UCPMP is expected to facilitate good marketing practices, increased levels of transparency and accountability across healthcare industry and remove ambiguity on all aspects of marketing by the pharmaceutical industries. The code covers various parameters like the general points to be followed by the industry, claims and comparisons related to other products, textual and audiovisual...
Words: 1441 - Pages: 6
...Nonetheless, because of patent lapses and new effective medication dispatches, the positioning of top pharmaceutical organizations always confronts various varieties. The most sold medication in 2003 was Lipitor made by Pfizer, with a worldwide piece of the pie of 2.2%, or identically deals worth $10.3 billion. Amid this time, there were 64 blockbusters (items creating over $ 1 billion in deals). Also, the pharmaceutical area has been portrayed with a high M&A action – a certainty that further adds to the consistent variety in the rankings and the dynamism of the pharmaceutical business by and large. For instance, in 2003, preceding the merger occurred, Aventis involved fifth spot, as measured by level of incomes, and Sanofi came in thirteenth. After the finish of the merger, Sanofi-Aventis rose as the third biggest organization in the business. In this manner, the immense...
Words: 920 - Pages: 4
...This report is to be submitted as "2008 Korea Pharmaceutical Industry Directory" as part of the "Actual analysis of Korean pharmaceutical Industry", Korea Health Industry Development Institute(KHIDI)'s own project. December 2008 ￭ ￭ ￭ • ⅰ Chapter 1. Outline of The Project 1. Objectives and Background of Investigation ◦The existing directory book has indicated limitations in promoting Korean pharmaceutical industry internationally or domestically, failing to offer practical help. ◦For this reason, this investigation is to have a thorough grasp of ranges of business and current status of investments and technology by pharmaceutical and companies to utilize and in to strengthen their industrial by competitiveness promoting them overseas collecting and offering basic data needed for promoting transfer of technology with home and abroad institutions. ◦Also, necessity for systematic and detailed data of industrial current status that can be utilized by companies who are making commitment for the development of pharmaceutical industry. 2. Targets and Contents of Directory Book 1) Targets for directory book •Korean Pharmaceutical companies: 81 companies. 2) Contents of directory book •Investigation items 3. Method and Way for Utilization 1) Method □ Ways to select investigation targets and to promote them were developed through consultation from consultation committees and domestic pharmaceutical companies (including unlisted ones) ◦Investigated...
Words: 30709 - Pages: 123
...FORCES | FAIBLESSES | * Leader sur le marché des vaccins * Leader sur les marchés émergents * Hausse du CA de la franchise diabète * Stabilité financière | * Dépendance du CA envers les meilleures et les médicaments célèbres * Fin des brevets des meilleures ventes en 2015 * Diminution de la productivité R&D | OPPORTUNITES | MENACES | * Augmentation de l'espérance de vie, hausse des troubles de santé * Hausse de la population et du niveau de vie dans les pays en développement * Croissance exponentielle des produits du marché pharmaceutique (vaccins, biotechnologies) | * Concurrence des médicaments génériques (pfizer, novartis, gsk..) * Baisse des dépenses du secteur de la santé dans les pays du Nord * Durcissement des réglementations liées à l'homologation des médicaments * Accroissement de la contrefaçon | Environnement | | Politique | Le secteur pharmaceutique est un secteur à la fois sensible et stratégique pour les gouvernements. Cette industrie est principalement présente dans les pays développés.Elle nécessite des financements important en recherche et développement et un système de protection social développés.Ainsi, des aides sont reversés par l’État pour soutenir la recherche scientifique et un système de protection sociale suffisamment développé pour permettre aux patients d’accéder aux soins et donc à la consommation des médicaments.Un autre aspect important concerne le régime...
Words: 813 - Pages: 4
...generic version of clopidogrel bisulfate, also known as Plavix. In addition, this paper will also explore how Sanofi-Aventis and Bristol-Meyers tried to maximize on forming monopolies to wean out their competitors, but instead caused more issues for their companies and how they FTC and state attorneys could have also shown a little more control and flexibility in making this agreement work for each party. Q1. Why did Bristol-Myers Squibb and Sanofi-Aventis seek a settlement rather than let the patent infringement case go to trial? The reason why Bristol-Myers Squibb and Sanofi-Aventis decided to seek a settlement could easily be because the patent infringement could have easily costs the companies more money if it were set to go to trial. In many instances, businesses pay more money by going directly to trial than settling out of court for a better result. Baron states, “Bristol-Myers Squibb and Sanofi – Aventis also agreed to pay Apotex at least $40 million if the agreement were approved and a $60 million break – up fee if the agreement would not receive antitrust approval” (Baron, 2010, p. 407). This settlement allowed Bristol Myers and Sanofi-Aventis the opportunity to buy more time in case the Federal Trade Commission decided more information was needed for the settlement. In addition, Fortado and Decker stated, “under the now-defunct settlement, Sanofi and Bristol-Myers agreed to cap damages that Apotex would have to pay should it begin sales of generic Plavix...
Words: 1279 - Pages: 6
...Executive Summary The diabetes market is expected to be over 500M cases by 2030. Sanofi’s Lantus has over 40% of the basal insulin market is the global leader in the diabetes solution space. However, came off patent in February 2015 and is at risk for competition from Eli Lilly. Sanofi needed to round out its diabetes portfolio and make up for lost revenue so it looked for an unmet consumer need. Afrezza helps Sanofi diversify its diabetes portfolio. Afrezza, is an inhalable insulin. It differentiates itself by providing a less painful and more convenient method of insulin administration for many patients. While the primary goal is to diversify itself from competition and generating lost revenues from Lantus , the greater opportunity lies in bringing transforming the diabetes solutions space. Overview of Diabetes Market As of 2014, there were 387M cases of diabetes worldwide which caused an estimated 1.5 million deaths globally. Diabetes is a chronic condition that has to be managed daily as it cannot be cured. Diabetes is the leading cause of amputations, blindness and many other health problems. The number of diabetes cases worldwide is expected to grow by an additional 205M cases by year 2030. There is a large financial incentive for companies to get into this space. As of 2012, the global insulin market was valued at $20B growing at a CAGR of 5.09% to $54B in 2030. Many of the new diabetes patients will have Type II and more and more Type II patients are using...
Words: 1200 - Pages: 5
...knowing this Sanofi is a company that strives to provide the assistant and health information needed to all our consumers. We not only want to provide them with free medication but we want to provide those that don’t qualify for the free program assistant with obtaining the medication they need. Keywords: Lantus, Sanofi, distribution, Medicare Part D, and copay Program Assistant Introduction Sanofi is a leading pharmaceutical company for many medications including Lantus diabetic insulin. Within the last year Sanofi has re-launched their Patient Assistant Programs which helps out a lot of diabetic patients that have no insurance or are underinsured. Knowing that within the next year or so every American will have to have insurance; we at Sanofi have decided to implement a new program called Copay and Medicare Part D Assistant Program. This program will assist those patients that have insurance therefore do not qualify for Patient Assistant, but need assistant with paying there copays. It will also assist the elderly with paying for their medication once they have reached the donut hole (this is when a Medicare Part D patient is responsible for the full cost of their medications). The Medicare Part D patients will need to have applied with Extra Help/ Low Income Subsidy (LIS) program which is offered through Medicare. If denied they will need to submit their letter of denial from Extra Help/ LIS to be eligible for Medicare Part D program assistant through Sanofi Patient Connection...
Words: 1095 - Pages: 5
...‘‘Business communication is a term that can be defined as the contact between the people in an organisation for the intention of carrying out the business activities. It is used to promote a product, service, or organization as well as pass on information within a business or work as an official statement from a company’’ (Business Communication, ask.com, 2013). Good communication skills are imperative for any business. In fact, these skills can often mean the difference between success and failure. There are two main types of business communication. Internal communication Internal communications is the function responsible for effective communication among participants within an organization. Also it refers to the sharing of information within an organization for business purposes. For example, internal communication within a company can take place via speech, telephone radio, mail, paging, fax, closed circuit television, electronic mail, Internet connections and computer networks. There are two sides to strategy in internal communications. In the first instance there is the organization's strategy — what it hopes to achieve and how it plans to go about achieving it. That strategy will be supported and, to some extent, delivered through effective internal communications. In this context internal communication can help on several different levels: * Tell: simply informing people of the direction, non-negotiable * Sell: anticipating some form of backlash, requiring...
Words: 3148 - Pages: 13
